Hillstream Biopharma (NASDAQ:CNTN) Director Sells $300,450.42 in Stock

Hillstream Biopharma Inc. (NASDAQ:CNTN) Director Gary Stetz sold 87,851 shares of Hillstream Biopharma stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $3.42, for a total value of $300,450.42. Following the sale, the director directly owned 146,675 shares of the company’s stock, valued at $501,628.50. This represents a 37.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Hillstream Biopharma Trading Down 1.8%

NASDAQ:CNTN traded down $0.06 during trading hours on Wednesday, hitting $3.23. 550,879 shares of the company’s stock traded hands, compared to its average volume of 756,064. The company has a market cap of $225.49 million, a price-to-earnings ratio of -2.81 and a beta of 1.44. Hillstream Biopharma Inc. has a 52 week low of $1.08 and a 52 week high of $9.08. The company has a fifty day moving average of $3.33.

Hillstream Biopharma (NASDAQ:CNTN) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.23) earnings per share (EPS) for the quarter.

Analyst Ratings Changes

Several research firms recently issued reports on CNTN. Weiss Ratings lowered Hillstream Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 15th. Wall Street Zen raised Hillstream Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Hillstream Biopharma presently has a consensus rating of “Sell”.

Hillstream Biopharma Company Profile

Hillstream BioPharma, Inc, a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company’s product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells.